142 related articles for article (PubMed ID: 17206723)
21. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
Ruemmele FM; Lachaux A; Cézard JP; Morali A; Maurage C; Giniès JL; Viola S; Goulet O; Lamireau T; Scaillon M; Breton A; Sarles J;
Inflamm Bowel Dis; 2009 Mar; 15(3):388-94. PubMed ID: 19023899
[TBL] [Abstract][Full Text] [Related]
22. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P;
Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865
[TBL] [Abstract][Full Text] [Related]
23. Predictors of response to Infliximab in children with luminal Crohn's disease.
Grover Z; Biron R; Carman N; Lewindon P
J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
[TBL] [Abstract][Full Text] [Related]
24. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of Crohn's disease treated with infliximab.
Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
[TBL] [Abstract][Full Text] [Related]
26. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
27. Review article: Medical therapy for fistulizing Crohn's disease.
Bressler B; Sands BE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
[TBL] [Abstract][Full Text] [Related]
28. Endoscopic monitoring of infliximab therapy in Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
[TBL] [Abstract][Full Text] [Related]
29. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
30. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
Dideberg V; Théâtre E; Farnir F; Vermeire S; Rutgeerts P; De Vos M; Belaiche J; Franchimont D; Van Gossum A; Louis E; Bours V
Pharmacogenet Genomics; 2006 Oct; 16(10):727-34. PubMed ID: 17001292
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease.
Yang BL; Chen YG; Gu YF; Chen HJ; Sun GD; Zhu P; Shao WJ
World J Gastroenterol; 2015 Feb; 21(8):2475-82. PubMed ID: 25741157
[TBL] [Abstract][Full Text] [Related]
32. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study.
Roumeguère P; Bouchard D; Pigot F; Castinel A; Juguet F; Gaye D; Capdepont M; Zerbib F; Laharie D
Inflamm Bowel Dis; 2011 Jan; 17(1):69-76. PubMed ID: 20623697
[TBL] [Abstract][Full Text] [Related]
33. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
Willot S; Vermeire S; Ohresser M; Rutgeerts P; Paintaud G; Belaiche J; De Vos M; Van Gossum A; Franchimont D; Colombel JF; Watier H; Louis E
Pharmacogenet Genomics; 2006 Jan; 16(1):37-42. PubMed ID: 16344720
[TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
35. Predictors of response to infliximab in luminal Crohn's disease.
Laharie D; Salzmann M; Boubekeur H; Richy F; Amouretti M; Quinton A; Couzigou P; Lamouliatte H; Zerbib F
Gastroenterol Clin Biol; 2005 Feb; 29(2):145-9. PubMed ID: 15795662
[TBL] [Abstract][Full Text] [Related]
36. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease.
Sánchez JM; Maldonado JC; Torres EA; Rivera C
P R Health Sci J; 2005 Mar; 24(1):11-7. PubMed ID: 15895872
[TBL] [Abstract][Full Text] [Related]
37. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
38. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
39. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease.
Fefferman DS; Lodhavia PJ; Alsahli M; Falchuk KR; Peppercorn MA; Shah SA; Farrell RJ
Inflamm Bowel Dis; 2004 Jul; 10(4):346-51. PubMed ID: 15475741
[TBL] [Abstract][Full Text] [Related]
40. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy.
Savoye-Collet C; Savoye G; Koning E; Dacher JN; Lerebours E
Inflamm Bowel Dis; 2011 Aug; 17(8):1751-8. PubMed ID: 21744430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
